General Repurposing References
Guy, R.K., Dipaola, R.S., Romanelli, F., and Dutch, R.E. (2020) Science
Avram, S., Curpan, R., Halip, L., Bora, A., and Oprea, T. (2020) Journal of Chemical Information and Modeling
Conti, R.M., Athey, S., Frank, R.G., and Gruber, J. (2020) Health Affairs
Zhang, L., Lionberger, R.A. (2020) Clinical Pharmacology & Therapeutics
BIO - Biotechnology Innovation Organization (2019)
Pushpakom, S., Iorio, F., Eyers, P. et al. (2019) Nature Reviews Drug Discovery
Shea, M.B., Stewart, M. , Van Dyke, H. , Ostermann, L. , Allen, J. , and Sigal, E. (2018) Therapeutic Innovation & Regulatory Science
Rees, S., Gribbon, P., Birmingham, K., Janzen, W.P., and Pairaudeau, G. (2016) Nature Reviews Drug Discovery
Frail, D.E., Brady, M., Escott, K.J., Holt, A., Sanganee, H.J., Pangalos, M.N., Watkins, C., and Wegner, C.D. (2015) Nature Reviews Drug Discovery
Editorial (2015) Nature Biotechnology
Persidis, A. (2011) Drug Discovery World
About: ASCPT and the disciplines of clinical pharmacology and translational science are poised to play a role in fighting the COVID-19 pandemic through the rigorous research of our members and committing to publishing top-notch research from all over the world. COVID-19 therapies will be, broadly speaking, repurposing of existing (approved) drugs in the short term, development of vaccines in the mid term, and discovery of new mechanisms of action and development of novel drugs in the long term. The research being published in the three journals of the ASCPT Journal Family reflects these varying horizons. We will be adding to this collection as more data become available, and as more treatments are considered.